Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...
New study published in Journal of Electromagnetic Biology and Medicine provides additional validation for Company’s ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Modeyso for patients with H3 K27M-mutant diffuse midline glioma. The therapy showed an overall ...
Please provide your email address to receive an email when new articles are posted on . Researchers recently presented early data on the efficacy of chimeric antigen receptor T-cell therapy for ...
DUBLIN, Sept. 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical ...
Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a ...
Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...
Diffuse midline glioma (DMG), H3K27-altered, is a lethal pediatric high-grade tumor, lacking effective treatment options, primarily depending on clinical trials. Epigenetic agent-based immunotherapy ...
Moleculin Biotech Inc. (NASDAQ:MBRX) shares fell 9.1% in premarket trading on Wednesday after the company disclosed results ...
HOUSTON, Texas (KTRK) -- Six months ago, we told you about a young woman who was diagnosed with a deadly brain tumor only found in children. She has been on a journey with Houston Methodist Hospital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback